Rula vs Danaher Corporation
Side-by-side comparison of AI visibility scores, market position, and capabilities
Mental health marketplace connecting patients with in-network therapists and psychiatrists, Los Angeles CA, raised $65M+. Insurance-covered access in all 50 states.
About
Rula is a Los Angeles, California-based mental health marketplace founded in 2019 that connects patients with in-network licensed therapists and psychiatrists through an online directory and matching platform. The company has raised over $65 million and has built insurance coverage across all 50 US states, making it one of the broadest-access in-network therapy platforms in the country. Rula handles provider credentialing, insurance contracting, billing, and claims processing on behalf of its network clinicians.\n\nRula's marketplace allows patients to search for therapists and psychiatrists by specialty, insurance, location, language, and availability, with real-time availability shown and direct booking enabled. The platform is designed to reduce the common friction points in finding in-network mental health care: lengthy wait times, confusing insurance directory inaccuracies, and billing surprises. Rula verifies insurance eligibility before the first appointment and provides upfront cost estimates so patients know their expected out-of-pocket responsibility.\n\nThe company has focused heavily on therapist experience and provider satisfaction, offering competitive reimbursement rates, automated billing, flexible scheduling, and dedicated support to attract and retain high-quality clinicians. Rula competes with Headway, Alma, and Grow Therapy in the therapist marketplace and infrastructure segment. With its 50-state insurance footprint and consumer-friendly search experience, Rula is positioned as an accessible alternative to the fragmented and often outdated directories maintained by health plans.
Washington DC life sciences instruments (NYSE: DHR) at $23.9B FY2024 revenue; Cytiva bioprocessing, Beckman Coulter diagnostics, biopharma destocking recovery, 2025 core revenue +3% guidance competing with Thermo Fisher.
About
Danaher Corporation is a Washington, D.C.-based global science and technology company — publicly traded on the New York Stock Exchange (NYSE: DHR) as an S&P 500 Health Care component — developing, manufacturing, and marketing analytical instruments, reagents, consumables, software, and services for life sciences research, clinical diagnostics, and environmental monitoring through approximately 65,000 employees worldwide. In fiscal year 2024, Danaher reported revenues of $23.9 billion (flat year-over-year) with non-GAAP core revenue declining 1% as the biopharma sector's inventory destocking cycle continued, with Q4 2024 revenue of $6.5 billion (+2.0% reported, +1.0% core) representing an inflection toward recovery, generating $6.7 billion in operating cash flow and $5.3 billion in free cash flow. Danaher guided 2025 core revenue growth of approximately 3% — marking the expected return to growth as biopharma customers who destocked pandemic-era bioprocessing supply surpluses return to normalized purchasing. CEO Rainer Blair leads Danaher's post-spinoff strategy: in September 2023, Danaher separated its Environmental & Applied Solutions segment as Veralto Corporation (NYSE: VLTO), creating two independent public companies — Danaher (pure-play life sciences and diagnostics) and Veralto (water quality and product identification). Danaher's current portfolio centers on bioprocessing (Cytiva's bioreactors, membranes, single-use manufacturing for drug production), clinical diagnostics (Beckman Coulter chemistry and hematology analyzers, Radiometer blood gas analyzers, Cepheid molecular diagnostics), and life sciences research instruments (SCIEX mass spectrometry, Leica Microsystems microscopy).
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.